Lipoprotein (a): Does It Play a Role in Pediatric Ischemic Stroke and Thrombosis?
- PMID: 37160656
- DOI: 10.1007/s11883-023-01102-5
Lipoprotein (a): Does It Play a Role in Pediatric Ischemic Stroke and Thrombosis?
Abstract
Purpose of review: The goal of this paper is to describe the current understanding of lipoprotein (a) (Lp(a)), clinical practice guidelines, and the potential pathophysiological mechanisms that appear to increase the risk of cardiovascular and thromboembolic events, specifically within the pediatric population.
Recent findings: The proatherogenic and pro-thrombotic properties of Lp(a) may increase the risk of atherothrombotic disease. In adults, atherosclerotic plaques increase thrombotic risk, but antifibrinolytic and proinflammatory properties appear to have an important role in children. Although it is not well established in neonates, recent studies indicate the risk of incident thrombosis and ischemic stroke are approximately fourfold higher in children with elevated Lp(a) which also increases their risk of recurrent events. Despite this higher risk, Pediatric Lp(a) screening guidelines continue to vary among different medical societies and countries. The inconsistency is likely related to inconclusive evidence outside of observational studies and the lack of specific therapies for children with elevated levels. Additional research is needed to improve understanding of the pro-thrombotic mechanisms of Lp(a), appropriate screening guidelines for Lp(a) in the pediatric population, and to elucidate the short and long term effects of elevated Lp(a) on the risk of pediatric thrombosis and stroke.
Keywords: Ischemic stroke; Lipoprotein (a); Pediatric stroke; Thrombosis.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
-
- Erqou S, Thompson A, Di Angelantonio E, Saleheen D, Kaptoge S, Marcovina S, et al. Apolipoprotein(a) isoforms and the risk of vascular disease. J Am Coll Cardiol. 2010;55:2160–7. https://doi.org/10.1016/j.jacc.2009.10.080 . - DOI - PubMed
-
- Hopewell JC, Seedorf U, Farrall M, Parish S, Kyriakou T, Goel A, et al. Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease. J Intern Med. 2014;276:260–8. https://doi.org/10.1111/joim.12187 . - DOI - PubMed
-
- Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med. 2012;273:6–30. https://doi.org/10.1111/j.1365-2796.2012.02592.x . - DOI - PubMed
-
- von Depka M, Nowak-Göttl U, Eisert R, Dieterich C, Barthels M, Scharrer I, et al. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood. 2000;96:3364–8. https://doi.org/10.1182/blood.V96.10.3364.h8003364_3364_3368 . - DOI
-
- Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: The longitudinal investigation of thromboembolism etiology. Arch Intern Med. 2002;162:1182–9. https://doi.org/10.1001/archinte.162.10.1182 . - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
